Anpac Bio-Medical Science Company CEO Dr. Chris Yu inspects one of the company's proprietary "Cancer Differentiation Analysis" (CDA) liquid biopsy technology devices before screening simple, standard blood tests signals of early disease. Anpac Bio's CDA technology consistently detects 26+ cancers, with a 75%-90% sensitivity/specificity rates, usually identifying the disease at its earliest stages. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission. Fully-commercialized with 200 patents filed worldwide, Anpac Bio and its respected medical research partners are celebrating #NationalCancerPreventionMonth by surpassing a new global milestone: processing 60,000+ independently-corroborated CDA tests for early cancer screening and detection; as well as monitoring cancer treatment, effectiveness, and recurrence. (Photo: Business Wire)

World-renowned, Second
Military Medical University and its affiliated Changhai
Hospital (CH) in Shanghai, China, have conducted 4,000+ CDA liquid
biopsy tests since 2014. Submitting Lung, Esophageal Cancer, and
cancer-free control group blood samples, “blinded” to Anpac Bio, CH
concluded CDA is a remarkably accurate, non-invasive test, supporting
both early diagnosis, and monitoring treatment effectiveness, prognosis,
and recurrence.

“Our preliminarily results indicate that CDA technology has better
sensitivity and specificity for early diagnosis, as well as potentially
a good tool for treatment assessment for Lung
Cancer and Esophageal
Cancer than traditional tumor
markers,” reports Dr. Jun-Jie Wu, Deputy Chief Physician, CH
Department of Oncology. “It (CDA) can also play a good role in
complementing chest CT (Computerized
Axial Tomography) screening for pulmonary
nodules. The existing data suggests that CDA technology is a
promising technology in the field of diagnosis and treatment assessment
of Lung Cancer and cancer of the Esophagus.”

According to study director and SCH Deputy Professor Dr.
Yuan Sheng Zang: “Initial results indicated that CDA technology has
better sensitivity and specificity for early-stage cancer screening than
that of traditional tumor markers. The evaluation on the significance of
CDA technology in prognosis is ongoing. The existing research data
suggest that CDA technology has a good prospect in the field of cancer diagnosis
and prognosis.”

Pioneering liquid biopsy research (launched in 2008), Anpac Bio is
already, fully-commercialized and generating revenue from Fortune 500
corporate, insurance, medical, research, and individual (“over the
counter”) testing; while most competing “liquid biopsy” research remains
in the laboratory and unavailable to the general public (for perhaps
years).

CDA’s independently-confirmed, very early stage cancer and pre-cancerous
disease detection’s efficiency and accuracy is due to the
technology’s multi-level and multi-parameter, patented design. With over
200 CDA-related patent applications worldwide (65+ currently issued),
CDA’s integrated system measures numerous protein, molecular, cellular,
and other factors, to identify disease signals. By enhancing signal
detection and processing, while reducing “noise”, the collected data is
subsequently analyzed using Anpac Bio’s proprietary algorithms.

“Every day, our company hears of other, potential ‘liquid biopsy’ tests
that report ‘someday’ may be used to catch cancer,” states Dr. Chris Yu,
Anpac Bio Chief Executive Officer. “Our CDA technology has been
extensively tested, verified, and used daily by dozens of Asia’s most
well-respected and renowned medical institutions. We are also generating
equally accurate and positive results in the United States. We’re very
proud that our CDA devices have advanced well-beyond the laboratory and
are processing real tests for real people – saving lives every day. On
this ‘National
Cancer Prevention Month’, Anpac Bio and our medical partners want
the world to know: ‘Someday’ is now!”